Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC.
[en] We report the results from a multicentre retrospective study of 220 adult patients who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT) for therapy-related acute myeloid leukaemia (t-AML). Median age at t-AML diagnosis was 56 years, with a prior history of haematological (45%) or breast (34%). Median time from cytotoxic exposure to t-AML diagnosis was 54.7 months. At transplant, around 20% of patients had measurable residual disease and 3% of patients were not in complete remission. The median follow-up was 21.4 months (Q1-Q3, 5.9-52.8). At 12 months, overall survival (OS), event-free survival (EFS), and graft-versus-host-disease (GVHD)-free-relapse-free survival (GRFS) were 60.7% (95% CI 54.6-67.5), 52.8% (95% CI 46.5-68.4), and 44.1% (95% CI 37.6-51.8), respectively. At 5 years, OS, EFS, and GRFS were 44.1% (95% CI 37.4-52.1), 40.4% (95% CI 33.9-48.1), and 35.3% (95% CI 28.8-43.3), respectively. At last follow-up, 44% of patients were in complete remission (n = 96) and transplant-related mortality accounted for 21% of all deaths (n = 119). Multivariable analysis revealed that uncontrolled t-AML at transplant was associated with lower EFS (HR 1.94, 95% CI 1.0-3.7, p = 0.041). In conclusion, alloHSCT for t-AML shows encouraging results and offers additional opportunity with the emergence of novel pre-graft therapies.
Disciplines :
Hematology
Author, co-author :
Rey, Gaëlle; Département d'hématologie clinique, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, France
Daguenet, Elisabeth; Département Universitaire de Recherche et d'Enseignement, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, France
Bonjean, Paul; Unité de Recherche Clinique Innovation Pharmacologique, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, France
Devillier, Raynier ; Institut Paoli Calmette, Marseille, France
Fegueux, Nathalie; Hôpital Saint Eloi, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
Forcade, Edouard ; Centre Hospitalier Universitaire Haut-Lévêque Magellan, Bordeaux, France
Srour, Micha ; Hôpital Claude Hurriez, Centre Hospitalier Universitaire de Lille, Lille, France
Chevallier, Patrice; Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France
Robin, Marie; Hôpital Saint-Louis, APHP, Université de Paris Cité, Paris, France
Suarez, Felipe; Hôpital Necker, Paris, France
Micol, Jean-Baptiste ; Institut Gustave Roussy, Villejuif, France
Labussière-Wallet, Hélène; Hôpital Lyon Sud, Centre Hospitalier Universitaire de Lyon, Lyon, France
Bilger, Karin; Centre Hospitalier Universitaire Hautepierre, Strasbourg, France
Daguindau, Etienne; Centre Hospitalier Universitaire Jean Minjoz, Besançon, France
Bay, Jacques-Olivier; Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
Fayard, Amandine; Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
Bulabois, Claude-Eric; Centre Hospitalier Universitaire de Grenoble, Grenoble, France
Nguyen-Quoc, Stéphanie; Hôpital Pitié-Salpêtrière, Paris, France
Genthon, Alexis; Hôpital Saint-Antoine, Paris, France
Orvain, Corentin ; Centre Hospitalier Universitaire d'Angers, Angers, France
Turlure, Pascal; Centre Hospitalier Universitaire Dupuytren, Limoges, France
Loschi, Michael ; Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France
Poiré, Xavier; Cliniques Universitaires St. Luc, Brussels, Belgium
Guillerm, Gaëlle; Centre Hospitalier Universitaire Augustin Morvan, Brest, France
Maillard, Natacha; Hôpital Jean Bernard, Poitiers, France
Mear, Jean-Baptiste; Centre Hospitalier Universitaire de Rennes, Rennes, France
Chalayer, Emilie; Département d'hématologie clinique, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, France
Cornillon, Jérôme; Département d'hématologie clinique, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, France
Tavernier, Emmanuelle ; Département d'hématologie clinique, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, France. emmanuelle.tavernier@chu-st-etienne.fr
Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC.
McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17:513–27. DOI: 10.1038/nrc.2017.60
Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. The role of TP53 mutations in the origin and evolution of therapy-related AML. Nature. 2015;518:552–5. DOI: 10.1038/nature13968
Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer. 2005;5:943–55. DOI: 10.1038/nrc1749
Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology. 2007;2007:453–9. DOI: 10.1182/asheducation-2007.1.453
Nenova I, Grudeva-Popova J. Carcinogenic potential of antitumor therapies - is the risk predictable? J BUON. 2017;22:1378–84.
Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood. 2013;121:2996–3004. DOI: 10.1182/blood-2012-08-448068
Cancer Survivorship --- United States, 1971–2001. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5324a3.htm (accessed 20 Sep2021).
Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363–85. DOI: 10.3322/caac.21565
Nilsson C, Linde F, Hulegårdh E, Garelius H, Lazarevic V, Antunovic P, et al. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications. Haematologica. 2022. 10.3324/haematol.2022.281233.
Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. JCO. 2015;33:3641–9. DOI: 10.1200/JCO.2014.60.0890
Churpek JE, Larson RA. The evolving challenge of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol. 2013;26:309–17. DOI: 10.1016/j.beha.2013.09.001
Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Derolf ÅR, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90:208–14. DOI: 10.1002/ajh.23908
Nampoothiri RV, Law AD, Lam W, Chen C, Al-Shaibani Z, Loach D, et al. Predictors of outcomes of therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2022;15:27–35.
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65. DOI: 10.1182/blood-2009-11-254441
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. DOI: 10.1182/blood-2016-08-733196
McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng G-S, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003–2007 versus 2013–2017 cohorts. Ann Intern Med. 2020;172:229. DOI: 10.7326/M19-2936
Metheny L, Callander NS, Hall AC, Zhang M-J, Bo-Subait K, Wang H-L, et al. Allogeneic transplantation to treat therapy-related myelodysplastic syndrome and acute myelogenous leukemia in adults. Transplant Cell Ther. 2021;27:923.e1–923.e12. DOI: 10.1016/j.jtct.2021.08.010
Döhner H, Wei AH, Löwenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18:577–90. DOI: 10.1038/s41571-021-00509-w
Lee CJ, Labopin M, Beelen D, Finke J, Blaise D, Ganser A, et al. Comparative outcomes of myeloablative and reduced‐intensity conditioning allogeneic hematopoietic cell transplantation for therapy‐related acute myeloid leukemia with prior solid tumor: a report from the acute leukemia working party of the European society for blood and bone marrow transplantation. Am J Hematol. 2019;94:431–8. DOI: 10.1002/ajh.25395
Bastida JM, Cabrero M, Lopez-Godino O, Lopez-Parra M, Sanchez-Guijo F, Lopez-Corral L, et al. Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome. Leuk Res. 2015;39:828–34. DOI: 10.1016/j.leukres.2015.05.003
Tomizawa D, Tanaka S, Kondo T, Hashii Y, Arai Y, Kudo K, et al. Allogeneic hematopoietic stem cell transplantation for adolescents and young adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23:1515–22. DOI: 10.1016/j.bbmt.2017.05.009
Goyal SD, Zhang M-J, Wang H-L, Akpek G, Copelan EA, Freytes C, et al. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transpl. 2015;50:1057–62. DOI: 10.1038/bmt.2015.82
Yokohama Cooperative Study Group for Hematology (YACHT), Ando T, Fujisawa S, Teshigawara H, Ogusa E, Ishii Y, et al. Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia. Int J Hematol. 2019;109:673–83. DOI: 10.1007/s12185-019-02647-5
Schmaelter A-K, Labopin M, Socié G, Itälä-Remes M, Blaise D, Yakoub-Agha I, et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. 2020;10:26. DOI: 10.1038/s41408-020-0296-3
Salas MQ, Chen S, Lam W, Pasic I, Gerbitz A, Michelis FV, et al. Less is more: superior graft-versus-host disease-free/relapse-free survival with reduced-intensity conditioning and dual T cell depletion in acute myelogenous leukemia. Biol Blood Marrow Transplant. 2020;26:1511–9. DOI: 10.1016/j.bbmt.2020.04.021
Gatwood KS, Labopin M, Savani BN, Finke J, Socie G, Beelen D, et al. Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. Bone Marrow Transpl. 2020;55:224–32. DOI: 10.1038/s41409-019-0673-3
Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, et al. Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the European Society for blood and bone marrow transplantation study. Biol Blood Marrow Transplant. 2018;24:1406–14. DOI: 10.1016/j.bbmt.2018.04.008
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9. DOI: 10.1182/blood-2005-05-2004
ElSawy M, Storer BE, Pulsipher MA, Maziarz RT, Bhatia S, Maris MB, et al. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol. 2015;170:574–83. DOI: 10.1111/bjh.13476
Jullien M, Orvain C, Berceanu A, Couturier M, Guillaume T, Peterlin P, et al. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post‐transplant cyclophosphamide. Cancer Med. 2021;10:7194–202. DOI: 10.1002/cam4.4262
Elsawy M, Storer BE, Milano F, Sandmaier BM, Delaney C, Salit RB, et al. Prognostic performance of the augmented hematopoietic cell transplantation-specific comorbidity/age index in recipients of allogeneic hematopoietic stem cell transplantation from alternative graft sources. Biol Blood Marrow Transplant. 2019;25:1045–52. DOI: 10.1016/j.bbmt.2018.11.030
D’Angelo CR, Novitsky B, Mee Lee S, Godley LA, Kline J, Larson RA, et al. Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019;60:629–38. DOI: 10.1080/10428194.2018.1493728
Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. CPX-351 (vyxeos) in AML. Leuk Lymphoma. 2020;61:288–97. DOI: 10.1080/10428194.2019.1660970
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid. Leuk JCO. 2018;36:2684–92. DOI: 10.1200/JCO.2017.77.6112
Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481–e491. DOI: 10.1016/S2352-3026(21)00134-4
Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5:5565–73. DOI: 10.1182/bloodadvances.2021005538
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29. DOI: 10.1056/NEJMoa2012971
